Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa.

ABSTRACT:

Background

The efficacy of bacille Calmette-Guérin (BCG) may be enhanced by heterologous vaccination strategies that boost the BCG-primed immune response. One leading booster vaccine, MVA85A (where "MVA" denotes "modified vaccinia virus Ankara"), has shown promising safety and immunogenicity in human trials performed in the United Kingdom. We investigated the safety and immunogenicity of MVA85A in mycobacteria-exposed--but Mycobacterium tuberculosis-uninfected--healthy adults from a region of South Africa where TB is endemic.

Methods

Twenty-four adults were vaccinated with MVA85A. All subjects were monitored for 1 year for adverse events and for immunological assessment.

Results

MVA85A vaccination was well tolerated and induced potent T cell responses, as measured by

SUBMITTER: Hawkridge T 

PROVIDER: S-EPMC2822902 | biostudies-literature | 2008 Aug

REPOSITORIES: biostudies-literature